Day One Biopharmaceuticals, Inc

Historical 13F Holders

Symbol
DAWN
CUSIP
23954D109
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 23954D109 since 12/18/2024, newest first.

Filer % of Class Filed
Vestal Point Capital, LP 13G/A Amendment 1
0% 5/15/2026
Event 3/31/2026
Atlas Venture Fund XI, L.P. 13G/A Amendment 4
0% 5/14/2026
Event 3/31/2026
AI Day1 LLC 13D/A Amendment 6
0% 4/27/2026
Event 4/23/2026
AI Day1 LLC 13D/A Amendment 5
12.5% 4/13/2026
Event 4/9/2026
FMR LLC 13G/A Amendment 6
0% 4/7/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 1 0% 3/26/2026
Event 3/13/2026
Glazer Capital, LLC 13G
5.4% 3/19/2026
Event 3/12/2026
Vestal Point Capital, LP 13G
5.1% 2/17/2026
Event 12/31/2025
FMR LLC 13G/A Amendment 5
5.6% 2/5/2026
Event 12/31/2025
FMR LLC 13G/A Amendment 4
9.9% 11/5/2025
Event 9/30/2025
RA Capital Management, L.P. 13G/A Amendment 4
0% 8/14/2025
Event 6/30/2025
FMR LLC 13G/A Amendment 3
11.2% 8/6/2025
Event 6/30/2025
BlackRock, Inc. 13G 5.8% 7/17/2025
Event 6/30/2025
BlackRock, Inc. 13G/A Amendment 1 4.7% 4/28/2025
Event 3/31/2025
RA Capital Management, L.P. 13G/A Amendment 3
5.7% 2/14/2025
Event 12/31/2024
FMR LLC 13G/A Amendment 2
12.8% 2/12/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 1 165 $3.55 k
2026 Q1 223 86.9 M $1.85 B
2025 Q4 204 81.5 M $759 M
2025 Q3 178 85.7 M $604 M
2025 Q2 184 86.6 M $563 M
2025 Q1 199 94.2 M $747 M
2024 Q4 176 93.7 M $1.19 B
2024 Q3 181 92.1 M $1.28 B
2024 Q2 177 75.0 M $1.03 B
2024 Q1 158 73.3 M $1.21 B
2023 Q4 148 79.1 M $1.16 B
2023 Q3 135 77.5 M $952 M
2023 Q2 149 78.8 M $941 M
2023 Q1 136 61.6 M $824 M
2022 Q4 118 63.2 M $1.35 B
2022 Q3 98 60.8 M $1.21 B
2022 Q2 95 59.4 M $1.06 B
2022 Q1 68 43.3 M $430 M
2021 Q4 60 42.0 M $708 M
2021 Q3 46 19.1 M $453 M
2021 Q2 35 18.5 M $418 M